Пожилой пациент с фибрилляцией предсердий и коморбидной патологией: возможности применения дабигатрана
https://doi.org/10.21518/2079-701X-2018-5-70-74
Аннотация
В статье рассматривается возможность назначения антикоагулянтной терапии пожилым пациентам с фибрилляцией предсердий в различных клинических ситуациях. Представлены ключевые данные рандомизированных клинических исследований по возможностям безопасного и эффективного использования прямого ингибитора тромбина в группах пожилых пациентов, перенесших ЧКВ, ОНМК/ТИА, а также у пациентов с сопутствующей хронической болезнью почек и сахарным диабетом.
Об авторах
Д. А. Напалков
Первый Московский государственный медицинский университет
Россия
д.м.н., профессор
Россия
д.м.н., профессор
А. А. Соколова
Первый Московский государственный медицинский университет
Россия
к.м.н.
Россия
к.м.н.
Список литературы
1. Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, Healey JS, Bell A, Pilote L, Andrade JG, Mitchell LB, Atzema C, Gladstone D, Sharma M, Verma S, Connolly S, Dorian P, Parkash R, Talajic M, Nattel S and Verma A for the CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. doi: 10.1016/j.cjca.2016.07.591
2. Lip GYH, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJGM, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP and Boriani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EUROobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot Registry). Eur Heart J, 2014, 35: 3365-3376. doi:10.1093/eurheartj/ehu374.
3. Gomez-Outes A, Suarez-Gea ML, Garcia-Pinilla JM. Causes of death in atrial fibrillation: Challenges and opportunities. Trends Cardiovasc Med, 2017, 27(7): 494-503. doi:10.1016/j. tcm.2017.05.002.
4. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39(3): 213-260. doi: 10.1093/eurheartj/ehx419.
5. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J, 2017 Mar 21, 38(12):852-859. doi: 10.1093/eurheartj/ehv643.
6. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med, 2016, 375(25): 2423-2434. doi: 10.1056/ NEJMoa1611594.
7. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators. Dual Anti thrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017, 377(16): 1513-1524. doi: 10.1056/NEJMoa1708454.
8. Hutcherson TC, Cieri-Hutcherson NE, Bhatt R. Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis. P T, 2017, 42(11): 692–698.
9. Åsberg S1, Eriksson M, Henriksson KM, Terént A. Reduced risk of death with warfarin – results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke. Int J Stroke, 2013, 8(8): 689-95. doi: 10.1111/j.1747-4949.2012.00855.
10. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S, RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol, 2010, 9(12): 1157-1163. doi: 10.1016/S1474-4422(10)70274-X.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361(12): 1139-51. doi: 10.1056/NEJMoa0905561.
12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365(10): 883-91. doi: 10.1056/ NEJMoa1009638.
13. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365(11): 981-92. doi: 10.1056/NEJMoa1107039.
14. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation, 2014, 129(9): 961-70. doi: 10.1161/ CIRCULATIONAHA.113.003628.
15. Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol, 2015, 65(23): 2481-93. doi: 10.1016/j.jacc.2015.03.577.
16. Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol, 2015, 196: 127-31. doi: 10.1016/j.ijcard.2015.05.141.
17. Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med, 2016 Nov 1, 176(11):1662-1671. doi: 10.1001/jamainternmed.2016.5954.
18. Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs, 2017, 17(1): 37-47. doi: 10.1007/s40256-016-0189-9.
Рецензия
Для цитирования:
Напалков ДА, Соколова АА. Пожилой пациент с фибрилляцией предсердий и коморбидной патологией: возможности применения дабигатрана. Медицинский Совет. 2018;(5):70-74. https://doi.org/10.21518/2079-701X-2018-5-70-74
For citation:
Napalkov DA, Sokolova AA. Elderly patient with atrial fibrillation and comorbid pathology: therapeutic potential of dabigatrane administration. Meditsinskiy sovet = Medical Council. 2018;(5):70-74. (In Russ.) https://doi.org/10.21518/2079-701X-2018-5-70-74
Просмотров:
545
Послать статью по эл. почте 